文献类型：期刊文献

英文题名：Characteristics and result reporting of registered COVID-19 clinical trials of Chinese and Indian traditional medicine: A comparative analysis

作者：Zhao, Nan[1];Pandey, Kritika[2];Lakshmanan, Skanthesh[2];Zhao, Ran[3];Fan, Jingchun[4];Zhang, Junhua[5];Bachmann, Max O.[6];Fan, Hong[1,3];Song, Fujian[6]

第一作者：Zhao, Nan

通信作者：Fan, H[1];Fan, H[2];Song, FJ[3]

机构：[1]Nanjing Med Univ, Sch Nursing, Nanjing, Peoples R China;[2]Aarogyam UK CIC, Integrat Ayurveda Network, Leicester, Leics, England;[3]Nanjing Med Univ, Sch Publ Hlth, Nanjing, Peoples R China;[4]Gansu Univ Tradit Chinese Med, Sch Publ Hlth, Lanzhou, Peoples R China;[5]Tianjin Univ Tradit Chinese Med, Evidence Based Med Ctr, Tianjin, Peoples R China;[6]Univ East Anglia, Fac Med & Hlth Sci, Norwich Med Sch, Norwich, England

第一机构：Nanjing Med Univ, Sch Nursing, Nanjing, Peoples R China

通信机构：[1]corresponding author), Nanjing Med Univ, Sch Nursing, Nanjing, Peoples R China;[2]corresponding author), Nanjing Med Univ, Sch Publ Hlth, Nanjing, Peoples R China;[3]corresponding author), Univ East Anglia, Fac Med & Hlth Sci, Norwich Med Sch, Norwich, England.

年份：2023

卷号：10

外文期刊名：FRONTIERS IN MEDICINE

收录：;Scopus(收录号：2-s2.0-85149643075);WOS:【SCI-EXPANDED(收录号:WOS:000942458800001)】；

语种：英文

外文关键词：COVID-19 clinical trials; China; India; traditional medicine; a comparative analysis

摘要：ObjectiveTo assess the main characteristics and result reporting of registered COVID-19 interventional trials of traditional Chinese medicine and traditional Indian medicine. Materials and methodsWe assessed design quality and result reporting of COVID-19 trials of traditional Chinese medicine (TCM) and traditional Indian medicine (TIM) registered before 10 February 2021, respectively, on Chinese Clinical Trial Registry (ChiCTR) and Clinical Trial Registry-India (CTRI). Comparison groups included registered COVID-19 trials of conventional medicine conducted in China (WMC), India (WMI), and in other countries (WMO). Cox regression analysis was used to assess the association between time from trial onset to result reporting and trial characteristics. ResultsThe proportion of COVID-19 trials investigating traditional medicine was 33.7% (130/386) among trials registered on ChiCTR, and 58.6% (266/454) on CTRI. Planned sample sizes were mostly small in all COVID-19 trials (median 100, IQR: 50-200). The proportion of trials that were randomized was 75.4 and 64.8%, respectively, for the TCM and TIM trials. Blinding measures were used in 6.2% of the TCM trials, and 23.6% of the TIM trials. Cox regression analysis revealed that planned COVID-19 clinical trials of traditional medicine were less likely to have results reported than trials of conventional medicine (hazard ratio 0.713, 95% confidence interval: 0.541-0.939; p = 0.0162). ConclusionThere were considerable between-country and within-country differences in design quality, target sample size, trial participants, and reporting of trial results. Registered COVID-19 clinical trials of traditional medicine were less likely to report results than trials of conventional medicine.